Recent, closed consultation topics are provided for information.
Date closed |
Consultation topic |
27 October 2024 |
Proposed
updates to the Guideline on the Regulation of Therapeutic
Products in New Zealand: Clinical Trials - Citizen Space |
14 December 2023 |
Proposed updates to the
Guideline on the Regulation of Therapeutic Products in New Zealand: Pharmacovigilance -
New Zealand Ministry of Health - Citizen Space
|
6 October 2023 |
Clozapine Survey 2023 - New Zealand Ministry of Health - Citizen Space
|
23 September 2022 |
Proposed warning and advisory statement for ocular decongestants
used for eye redness and/or minor eye irritation
|
4 April 2022 |
Proposed warning and advisory statement relating to the harm of opioid abuse, misuse, and dependence |
8 November 2021 |
Proposed warning and advisory statements relating to the harm of long-term
use and overuse of stimulant laxatives |
8 April 2021 |
Review of Fees payable under the Medicines Act 1981 |
22 March 2021 |
Consultation on Plan to update the New Zealand Code of Good
Manufacturing Practice |
30 April 2020 |
Consultation on Contraceptive Standards |
31 January 2020 |
Consultation on proposed changes to current warning and advisory statements for paracetamol |
07 August 2019 |
Medicinal Cannabis Scheme Consultation |
08 August 2019 |
Proposed warning statements for substances (eg, allergens) in
medicines that may cause undesirable reactions |
08 August 2019 |
Changes to the prescribing restrictions for riluzole |
18 April 2019 |
Therapeutic Products Regulatory Scheme consultation |
7 December 2018 |
Proposed warning statement regarding a fire hazard on the labels
of paraffin-based skin products |
3 August 2018 |
Update to the Guideline on the Regulation of Therapeutic Products
- Part 11: Clinical Trials |
31 May 2018 |
Consultation
on the revision of CMN Form B |
27 April 2018 |
Review of fees payable under
the Medicines Regulations 1984
|
15 January 2018 |
Updating the guidance document 'How to change the legal classification
of a medicine in New Zealand |
15 January 2018 |
Observers at Ministerial Advisory Committee meetings
|
29 September 2017 |
Changes to the Label Statements Database for sedating antihistamines
available without prescription |
15 September 2017 |
Proposed change
to warning statements on labels of oral non-steroidal anti-inflammatory
drugs (NSAIDs) available without a prescription |
13 April 2017 |
Addition of warning statements on labels of topical miconazole
containing medicines available without prescription |
11 November 2016 |
Change to warning statements on labels of OTC loratadine and
desloratadine medicines |
31 March 2016 |
Consultation on Changes
to the Data sheet format, process and the Data sheet guideline |
22 June 2015 |
Addition
of warning statements on labels of OTC oral and topical diclofenac
medicines |
13 May 2015 |
Guideline on the
Regulation of Therapeutic Products in New Zealand. Part 8: Pharmacovigilance |
27 February 2015 |
New Zealand Medicines and Medical
Devices Recall Code |
9 January 2015 |
Proposed amendment to the Medicine Regulations 1984 re fluoride
in drinking water |
21 March 2014 |
Ministry of Health consultation on Psychoactive Substances Regulations |
3 March 2014 |
Removal
of warning statements from Label Statements Database for loratadine
and cetirizine |
3 March 2014 |
Changes
to the Label Statements Database for codeine-containing medicines |
3 March 2014 |
Changes
to the Label Statements Database for aspirin |
3 March 2014 |
Changes
to the prescribing restrictions for clozapine |
28 February 2014 |
Proposed
revision of abbreviated process policy |
18 October 2013 |
Consultation on the classification
of peptide-based performance and image enhancing drugs |
27 September 2013 |
Standards for Contraceptive
Devices supplied in New Zealand |
10 July 2013 |
Common Regulatory Framework Harmonisation
Proposal: International Harmonisation of Ingredient Names |
14 June 2013 |
Classification of
peptide-based performance and image enhancing drugs |
7 April 2013 |
Trans-Tasman
Early Warning System of Safety Concerns with Medicines and Medical
Devices |
28 February 2013 |
Medsafe signals planned changes to packaging requirements for
antidepressants |
21 February 2013 |
Description
of a possible joint regulatory scheme for therapeutic products
under ANZTPA |
31 January 2013 |
Planned
changes to GMP evidence required for active pharmaceutical ingredients
|
7 November 2012 |
Over-the-Counter
(OTC) Medicines Business Process Reform Consultation Paper |
25 May 2012 |
Proposed Business
Rule for Publication of Data Sheets |
27 August 2010 |
Uniform Recall
Procedure for Medicines and Medical Devices (the Recall code) |
26 March 2010 |
Proposal to
widen prescriber access to clozapine |
30 November 2009 |
Proposed
updates to the New Zealand Good Clinical Research Practice Guideline
|
20 November 2009 |
Submission
and publication processes for data sheets and Consumer Medicine
Information on the Medsafe website |
29 May 2009 |
Review
of Administrative Processes Associated with the Evaluation and
Classification of Medicines |
22 May 2009 |
Proposed
changes to fees payable under the Medicines Regulations 1984
(PDF document, 83 KB, 9 pages)
Medsafe Report
(PDF document, 108 KB, 15 pages)
Deloitte Report.pdf
(PDF document, 112 KB, 28 pages) |
15 May 2009 |
Proposed
update to the New Zealand Code of Good Manufacturing Practice |